Oxford, UK – 13 May 2014: Oxford BioMedica plc (LSE: OXB), (“the Company”) the leading gene based biopharmaceutical company, today publishes its interim management statement for the period 1 January to 12 May 2014.
OXB-102 / ProSavin®
LentiVector® platform revenues
John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Consistent with what we highlighted in our recent 2013 preliminary results, Oxford BioMedica is now in its strongest ever operational position. This is due to its leading LentiVector® development pipeline and specialist LentiVector® manufacturing capabilities, in addition to the strength of its intellectual property in the rapidly expanding Lentivector® environment. We look forward to rectifying the cash position and I am confident that we will go on to build a substantial and sustainable gene and cell therapy business.”
Notes to editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
For further information please contact
Oxford BioMedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications – Media Enquiries
Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips
Tel: +44 (0)20 3709 5700